Tag: resolution

ROAD TOWN, British Virgin Islands, July 14, 2026 (GLOBE NEWSWIRE) -- TxFlow L1, the Layer 1 blockchain powering a multi-application onchain financial ecosystem built around its TIP Liquidity Standards, today announced its second Channel: Probly, the first prediction-market application built on TxFlow Improvement Protocol 3 (TIP3).

Upchurch Watson White & Max Mediation Group recently welcomed veteran trial attorney Frank Harris Cole Jr. to its panel of mediators, adding 40 more years of experience representing clients in complex civil litigation throughout Florida.

REGINA, Saskatchewan, June 26, 2026 (GLOBE NEWSWIRE) -- Information Services Corporation (TSX:ISC) (“ISC” or the “Company”) is pleased to announce that, at the special meeting (the “Meeting”) of shareholders held earlier today, ISC shareholders (“Shareholders”) voted in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Transaction”) under The Business Corporations Act, 2021 (Saskatchewan) (the “SBCA”), pursuant to which a wholly-owned subsidiary of Plenary Americas LP (“Plenary Americas”) will acquire all of the issued and outstanding Class A Limited Voting Shares (the “Shares”) of ISC at a price per Share of CAD$51.00 (other than those Shares held by certain members of ISC’s senior management who have entered into equity rollover agreements to retain an interest in ISC following closing of the Transaction in respect of the Shares owned by them (the “Rollover Shareholders”)).

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4

Charenton-le-Pont, 26 June 2026

Generated Record Operating Cash Flow of $54.1 Million; Maintained Profitability